Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.
You may also be interested in...
Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients
Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.
Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients
Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.
Merck Builds On Januvia Momentum With Two Supplementary Claims
Recently announced sNDAs have October action dates and seek indications relating to initial and add-on use with metformin or sulfonylureas.